400 North Capitol Street, NW
Washington, DC 20001
- Toll Free 1.888.564.6273
- Local 202.783.3870
CAPITOL HILL. FreedomWorks today hosted a policy briefing on the issue of regulating biogeneric medicines. FreedomWorks Chief Economist, Wayne Brough, moderated the discussion which featured Dr. Everett Ehrlich, President of the ESC Company, Greg Conko, Senior Fellow at The Competitive Enterprise Institute, and Dr. Gillian Woollett, Chief Scientist at Engel and Novitt.
More than 30 attended, including professional Hill staff from the House and Senate, as well as representatives from the health care industry and other free-market organizations. The panel reinforced the need for an efficient regulatory pathway for biogeneric medicines to enhance competition and foster innovation in this critical market.
It was clear during the Q & A section, as Hill staffers discussed various legislative proposals, that this issue is gaining significant momentum in the 110th Congress.